AMG 714 for Diet Non-Responsive Celiac Disease and Refractory Celiac Disease Type II (RCD-II)

AMG 714 is a fully human immunoglobulin monoclonal antibody that binds to IL-15 and neutralizes its effect.

AMG 714 has been studied in approximately 200 patients with rheumatoid arthritis and psoriasis, as well as in healthy volunteers. In a Phase 1b study of AMG 714 in rheumatoid arthritis, which has been published by Baslund and collaborators, AMG 714 appeared to have biological activity and demonstrated a safety profile comparable to placebo.

The selectivity, safety and pharmacokinetic profile, in conjunction with the evidence of activity in rheumatoid arthritis, supports the testing of AMG 714 in celiac disease and Type II refractory celiac disease.

Celimmune has initiated and completed enrollment in Phase 2 studies of AMG 714 for the treatment of diet non-responsive celiac disease and RCD-II, an in situ small bowel T cell lymphoma.

Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005; 52:2686-2692.

NRCD Trial
RCD-II Trial